Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

simvastatin

- PMLiVE

Merck & Co signs cancer vaccines research deal for Keytruda

Will work on range of personalised vaccines to complement its blockbuster

- PMLiVE

FDA approves Gilead’s ‘universal’ hep C combination Epclusa

Adds a third Sovaldi-based treatment to the firm’s portfolio

Roche Basel Switzerland

Roche’s MS drug Ocrevus awarded priority review by FDA

Comes as Swiss company files the therapy with the FDA and EMA

- PMLiVE

Teva’s asthma treatment Cinqaero set for European approval

CHMP backs the antibody therapy for eosinophilic asthma

- PMLiVE

Merck starts pivotal trials of new antibiotic combination

Continues testing after positive phase II results for relebactam addition 

- PMLiVE

Ariad files early marketing application for brigatinib

Second-line lung cancer therapy could be on the market by early 2017

- PMLiVE

Trial backs Keytruda use first-line in lung cancer

Suggests Merck & Co’s drug is more effective than chemotherapy for NSCLC patients

Shire Basingstoke

Shire receives FDA nod for self-infusion of Glassia

The company has also struck a deal with Pfizer to expand its GI portfolio

- PMLiVE

Updated EMPA-REG data show Jardiance also protects kidney

Boehringer Ingelheim and Lilly’s drug is the first to show positive impact on kidney damage

- PMLiVE

Teva suspends migraine patch on burn reports

FDA issues safety alert and instigates investigation into Zecuity

- PMLiVE

FDA approves first cholera vaccine in US

PaxVax’s oral vaccine Vaxchora will be launched by September

- PMLiVE

Merck buys cough drug developer Afferent for $1.25bn

Gains access to pipeline with potential for development in ‘neurogenic’ indications

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links